Age-Related Macular Degeneration (AMD) Treatment Market by Treatment Type (Anti-VEGF Therapy, Photodynamic Therapy, Laser Therapy, Corticosteroid Treatment, Combination Therapy), Stage (Early AMD, Intermediate AMD, Late AMD), Distribution Channel (Hospitals & Clinics, Ambulatory Surgical Centers, Specialty Clinics, Retail Pharmacies, Online Pharmacies), and Region; Global Insights & Forecast (2024–2030)

As per Intent Market Research, the Age-Related Macular Degeneration Treatment Market was valued at USD 11.1 billion in 2023 and will surpass USD 18.9 billion by 2030; growing at a CAGR of 7.9% during 2024 - 2030.

The age-related macular degeneration (AMD) treatment market has seen remarkable growth driven by an aging population, increasing prevalence of AMD, and technological advancements in therapeutic options. AMD, a leading cause of visual impairment, primarily affects the central vision. The market is diversified, offering solutions ranging from anti-VEGF therapies to corticosteroid treatments, catering to different stages of the disease. As pharmaceutical innovation progresses, targeted therapies and advanced delivery methods continue to shape the landscape.

Anti-VEGF Therapy Segment is Largest Owing to Its Proven Efficacy

Anti-VEGF therapy dominates the treatment type segment, holding the largest market share due to its established efficacy in managing wet AMD. Drugs like aflibercept and ranibizumab have become the gold standard, significantly reducing fluid accumulation in the retina and slowing disease progression.

These therapies are well-supported by a robust body of clinical evidence and are widely adopted by healthcare professionals. Their recurring administration schedules ensure consistent revenue streams for market players, reinforcing their dominant position in this segment. Expanding indications and combination approaches further drive growth for anti-VEGF treatments.

Late AMD Segment Fastest Growing Due to Advanced Solutions for Wet AMD

The late AMD segment, particularly wet AMD, is the fastest-growing category, reflecting advancements in treatment modalities for this severe stage of the disease. Late AMD is characterized by either neovascularization (wet AMD) or geographic atrophy (advanced dry AMD), requiring targeted and innovative treatments.

Wet AMD, driven by abnormal blood vessel growth, benefits immensely from anti-VEGF agents and ongoing developments in sustained-release formulations. Simultaneously, emerging therapies for dry AMD, such as complement inhibitors, are gaining traction, addressing an unmet need and boosting growth within this segment.

Online Pharmacies Segment Fastest Growing Owing to Convenience and Accessibility

The online pharmacies segment is experiencing rapid growth within the distribution channel due to its convenience, accessibility, and increasing adoption of digital platforms by consumers. Elderly patients, who represent a significant proportion of AMD cases, are increasingly embracing online solutions for prescription refills and medication deliveries.

With digital health advancements, online pharmacies offer a seamless experience, including consultations and medication management tools. The shift to telehealth during the pandemic has further bolstered this trend, making online platforms a critical growth area for AMD treatment distribution.

North America Leads the Market Due to High Prevalence and Advanced Infrastructure

North America holds the largest share of the AMD treatment market, driven by high disease prevalence, advanced healthcare infrastructure, and strong reimbursement frameworks. The region benefits from early adoption of innovative therapies and a well-established regulatory environment that accelerates drug approvals and market access.

In addition, active investments in R&D by key pharmaceutical companies headquartered in the U.S. contribute to the dominance of this region. Public awareness campaigns and government initiatives supporting vision health further augment market growth in North America.

Leading Companies and Competitive Landscape

The AMD treatment market is highly competitive, with companies like Regeneron, Novartis, and Roche leading the space with their blockbuster drugs. Collaborations and licensing agreements are common strategies among competitors, enabling the development of novel therapies. Emerging players like Kodiak Sciences and Apellis Pharmaceuticals are introducing innovative products, intensifying market competition.

Advances in gene therapy and extended-duration anti-VEGF formulations are set to redefine the competitive dynamics, encouraging both established and emerging companies to continually innovate. These factors collectively position the AMD treatment market for sustained growth in the years ahead

Recent Developments:

• Regeneron Expands Eylea Label: Approval for 8 mg dose in wet AMD by the U.S. FDA (October 2023).
• Novartis Advances Beovu: Completed Phase III trial for extended dosing in AMD patients (September 2023).
• Roche Collaborates with Kodiak Sciences: Co-developing advanced anti-VEGF agents for macular diseases (August 2023).
• FDA Approval for Apellis: Received clearance for intravitreal pegcetacoplan for advanced dry AMD (July 2023).
• Acquisition News: AbbVie acquires Allergan’s ophthalmology portfolio to expand AMD solutions (June 2023)

List of Leading Companies:

• Regeneron Pharmaceuticals, Inc.
• Novartis AG
• Bayer AG
• Roche Holding AG
• Pfizer Inc.
• Allergan (AbbVie)
• Kodiak Sciences Inc.
• Adverum Biotechnologies
• Outlook Therapeutics, Inc.
• Ophthotech Corporation
• Apellis Pharmaceuticals, Inc.
• Iveric Bio (formerly Ophthotech)
• Alimera Sciences
• Graybug Vision, Inc.
• Biogen Inc

Report Scope: